CureVac (NASDAQ:CVAC) Shares Gap Up – Here’s What Happened

Shares of CureVac (NASDAQ:CVAC) gapped up before the market opened on Tuesday . The stock had previously closed at $3.00, but opened at $3.08. CureVac shares last traded at $2.97, with a volume of 116,822 shares trading hands.

Analyst Ratings Changes

Separately, JMP Securities reaffirmed a “market outperform” rating and issued a $16.00 target price on shares of CureVac in a report on Friday, February 14th.

CureVac Trading Down 2.5 %

The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20. The company has a market capitalization of $654.85 million, a PE ratio of 5.32 and a beta of 2.53. The stock has a fifty day moving average of $3.47 and a 200 day moving average of $3.19.

Hedge Funds Weigh In On CureVac

Several hedge funds have recently modified their holdings of CVAC. Integrated Wealth Concepts LLC bought a new stake in CureVac in the 3rd quarter valued at $35,000. Two Sigma Advisers LP purchased a new position in shares of CureVac during the fourth quarter valued at about $48,000. Jump Financial LLC bought a new stake in shares of CureVac in the fourth quarter worth about $55,000. D. E. Shaw & Co. Inc. purchased a new stake in shares of CureVac in the fourth quarter worth about $66,000. Finally, Barclays PLC bought a new position in CureVac during the third quarter valued at approximately $67,000. Hedge funds and other institutional investors own 17.26% of the company’s stock.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.